Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | HTT | P42858 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679065 | 1.00 | GFER (0.53) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2724952 | 0.92 | GFER (0.44) | GFERMAPTHTTMEN1KMT2A | |
| Iodide SCHEMBL16906337 | 0.91 | GFER (0.44) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL15313243 | 0.90 | MAPT (0.49) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2724960 | 0.89 | KMT2A (0.51) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2725194 | 0.89 | GFER (0.54) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2723101 | 0.88 | KMT2A (0.64) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2723746 | 0.88 | MTNR1A (0.50) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2723789 | 0.88 | GFER (0.53) | GFERMAPTHTTMEN1KMT2A | |
| SCHEMBL2723190 | 0.87 | KMT2A (0.54) | GFERMAPTHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | claimed |
| EP-4268814-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2023-11-01 | — | — | EP | claimed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | claimed |
| US-20210069184-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2021-03-11 | — | — | US | claimed |
| US-20190192508-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2019-06-27 | — | — | US | claimed |
| US-20190008865-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2019-01-10 | — | — | US | claimed |
| US-10137123-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2018-11-27 | — | — | US | claimed |
| EP-3393462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | Arizona Board of Regents on behalf of the University of Arizona (US) | 2018-10-31 | — | — | EP | claimed |
| US-20170231982-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2017-08-17 | — | — | US | claimed |
| WO-2017112693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-29 | — | — | WO | claimed |
| US-20150352105-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-12-10 | — | — | US | claimed |
| US-9084786-B2 | Methods and compositions for prevention and treatmentof cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2015-07-21 | — | — | US | claimed |
| US-20130274271-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENTOF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2013-10-17 | — | — | US | claimed |
| EP-2614860-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2013-07-17 | — | — | EP | claimed |
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-29 | — | — | US | claimed |
| EP-1366020-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | claimed |
| WO-2002072536-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-19 | — | — | WO | claimed |
| US-12403139-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2025-09-02 | — | — | US | disclosed |
| EP-1366020-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072536-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | UTS2R, TRPV1, VRK1 | GFER 1592/4885MAPT 2208/4885HTT 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.